Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …

Immune-checkpoint blockade (ICB) therapies represent a paradigm shift in the treatment of
human cancers; however, it remains incompletely understood how tumor-reactive T cells …

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …

Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate …

Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …

A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

Despite a prevailing dogma wherein antibody drug conjugates (ADCs) increase the
maximum tolerated dose of potent cytotoxin payloads while lowering the minimum effective …

Combination chemotherapy can cure certain leukemias and lymphomas, but most solid
cancers are only curable at early stages. We review quantitative principles that explain the …

Current cancer therapy includes a variety of strategies that can comprise only one type of
treatment or a combination of multiple treatments. Chemotherapy is still the gold standard for …